EBIT: Income before interest and taxes.
Medicenna Therapeutics Corp. (MDNAF) had EBIT of $-3.66M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-3.71M |
|
-- |
|
-- |
|
$3.66M |
|
$-3.66M |
|
$-0.05M |
|
$-3.71M |
|
$-3.71M |
|
$-3.71M |
|
$-3.71M |
|
$-3.71M |
|
$-3.71M |
|
|
EBIT |
$-3.66M |
$-3.64M |
|
78.01M |
|
78.01M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$22.86M |
|
$0.01M |
|
$0.16M |
|
$23.03M |
|
$2.27M |
|
-- |
|
$8.29M |
|
$10.56M |
|
$12.46M |
|
$12.43M |
|
$12.46M |
|
78.22M |
|
| Cash Flow Statement Financials | |
$-8.21M |
|
$-0.02M |
|
$16.79M |
|
$12.13M |
|
$21.42M |
|
$9.29M |
|
$1.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-29.75% |
|
-29.84% |
|
-16.10% |
|
-29.75% |
|
$0.16 |
|
$-0.11 |
|
$-0.11 |
|